Categories Earnings, Health Care

ACADIA Pharmaceuticals (ACAD): Q3 2019 Earnings Snapshot

— ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) reported Q3 2019 loss of $0.29 per share, vs. $0.40 expected.

— Revenues grew 62% to $94.6 million, vs. $88.4 million expected.

— Research and development expenses were $62.6 million, compared to $53.1 million last year.

— FY19 NUPLAZID net sales guidance is increased to $330 million to $340 million from the previous range of $320 million to $330 million.

— ACAD shares fell 0.81% following the announcement.

Get access to timely and accurate verbatim transcripts that are published within hours of the event.

Most Popular

Seagate Technology beats Q1 earnings estimate: Infographic

Seagate Technology (NYSE: ALK) reported first-quarter 2022 financial results before the regular market hours on Friday. The company reported Q1 revenue of $3.12 billion, up 35% year-over-year and higher than

Infographic: Schlumberger (SLB) Q3 2021 Earnings Results

Schlumberger Limited (NYSE: SLB) came up with its third-quarter 2021 results on Friday. Revenue increased to $5.8 billion from $5.2 billion last year. Analysts had expected revenue of $5.09 billion.

Honeywell (HON) Q3 2021 Earnings: Key financials and quarterly highlights

Honeywell International Inc. (NASDAQ: HON) reported third quarter 2021 earnings results today. Sales increased 9% year-over-year to $8.4 billion but missed projections of $8.6 billion. On an organic basis, sales


Add Comment
Viewing Highlight